Evidence map›Paper›PMID 38542223›Full record

ArticleInternational journal of molecular sciences2024

Trimetazidine Improves Mitochondrial Dysfunction in SOD1

Illari Salvatori, Valentina Nesci, Alida Spalloni, Veronica Marabitti, Maurizio Muzzi, Henri Zenuni, Silvia Scaricamazza, Marco Rosina, Gianmarco Fenili, Mariangela Goglia and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Illari SalvatoriDepartment of Experimental Medicine, University of Roma "La Sapienza", 00185 Rome, Italy.
Valentina NesciIRCCS, Fondazione Santa Lucia, 00179 Rome, Italy.
Alida SpalloniIRCCS, Fondazione Santa Lucia, 00179 Rome, Italy.
Veronica MarabittiDepartment of Biology, Tor Vergata University of Rome, 00133 Rome, Italy.ORCID 0000-0001-5941-9656
Maurizio MuzziDepartment of Science, LIME, University of Roma Tre, 00165 Rome, Italy.
Henri ZenuniUnit of Neurology, Fondazione PTV Policlinico Tor Vergata, 00133 Rome, Italy.
Silvia ScaricamazzaIRCCS, Fondazione Santa Lucia, 00179 Rome, Italy.
Marco RosinaIRCCS, Fondazione Santa Lucia, 00179 Rome, Italy.ORCID 0000-0003-0952-1710
Gianmarco FeniliDepartment of Movement, Human and Health Sciences, University of Rome "Foro Italico", 00135 Rome, Italy.ORCID 0009-0009-0940-1779
Mariangela GogliaUnit of Neurology, Fondazione PTV Policlinico Tor Vergata, 00133 Rome, Italy.ORCID 0009-0006-4128-5876
Laura BoffaUnit of Neurology, Fondazione PTV Policlinico Tor Vergata, 00133 Rome, Italy.
Roberto MassaUnit of Neurology, Fondazione PTV Policlinico Tor Vergata, 00133 Rome, Italy.
Sandra MorenoDepartment of Science, LIME, University of Roma Tre, 00165 Rome, Italy.ORCID 0000-0002-1079-3222
Nicola Biagio MercuriIRCCS, Fondazione Santa Lucia, 00179 Rome, Italy.ORCID 0000-0001-6700-7491
Francesca NazioDepartment of Biology, Tor Vergata University of Rome, 00133 Rome, Italy.ORCID 0000-0002-3039-4448
Patrizia LongoneIRCCS, Fondazione Santa Lucia, 00179 Rome, Italy.ORCID 0000-0001-8964-1637
Alberto FerriIRCCS, Fondazione Santa Lucia, 00179 Rome, Italy.ORCID 0000-0002-4097-0605
Cristiana ValleIRCCS, Fondazione Santa Lucia, 00179 Rome, Italy.ORCID 0000-0002-0914-6511
Policlinico Tor Vergata · ITFondazione Santa Lucia · ITUniversity of Rome Tor Vergata · ITIstituto di Farmacologia Traslazionale · ITRoma Tre University · ITForo Italico University of Rome · IT

Funding

Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica HyperALSFondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica 'Unraveling the protective effects of NOS1AP in the rescue of TDP-43 loss of function pathological mechanismsItalian Association for Cancer Research Ref. 27019Ministero della Salute RF-2019-12369105Ministero dell'Università e Ricerca Italy The Grant of Excellence Departments 2023-2027National Research Council CNR IFT DBA.AD005.225 -NUTRAGE- FOE2021Regione Lazio Prot. GeCoWEB n. A0375-2020- 36668
6 · The paper itself

Abstract

Amyotrophic Lateral Sclerosis (ALS) is considered the prototype of motor neuron disease, characterized by motor neuron loss and muscle waste. A well-established pathogenic hallmark of ALS is mitochondrial failure, leading to bioenergetic deficits. So far, pharmacological interventions for the disease have proven ineffective. Trimetazidine (TMZ) is described as a metabolic modulator acting on different cellular pathways. Its efficacy in enhancing muscular and cardiovascular performance has been widely described, although its molecular target remains elusive. We addressed the molecular mechanisms underlying TMZ action on neuronal experimental paradigms. To this aim, we treated murine SOD1

Indexed as

Amyotrophic Lateral SclerosisMitochondrial DiseasesTrimetazidineAnimalsAutophagyDisease Models, AnimalHumansLeukocytes, MononuclearMiceMice, TransgenicSuperoxide DismutaseSuperoxide Dismutase-1SOD1 protein, humanSuperoxide DismutaseSuperoxide Dismutase-1TrimetazidineAmyotrophic Lateral SclerosisautophagymitochondriaSOD1G93Aspinal and cortical primary culturesTrimetazidine

Identifiers

PMID38542223
PMCPMC10970050
OpenAlexW4392762946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.